Immune effector cells produce lethal DNA damage in cells treated with a thiopurine
- PMID: 19244103
- PMCID: PMC2658672
- DOI: 10.1158/0008-5472.CAN-08-4264
Immune effector cells produce lethal DNA damage in cells treated with a thiopurine
Abstract
Azathioprine, a widely used immunosuppressant, is also used in the control of inflammatory disorders. These are characterized by the local accumulation of immune effector cells that produce reactive oxygen species (ROS). The DNA of azathioprine-treated patients contains 6-thioguanine (6-TG), a base analogue that is particularly susceptible to oxidation. Here, we show that 6-TG is vulnerable to ROS produced by chemical oxidants and that cells containing DNA 6-TG are hypersensitive to these oxidants. We also show that 6-TG incorporated into the DNA of macrophages sensitizes them to killing by endogenously produced ROS. ROS generated by macrophages are also a hazard for cocultured nonmacrophage cells containing DNA 6-TG. This bystander vulnerability of cells containing DNA 6-TG to oxidation by ROS generated by immune effector cells has implications for the long-term use of azathioprine in the management of inflammatory disorders.
Figures
References
-
- Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease. Cancer. 2001;91:854–62. - PubMed
-
- Gaffney K, Scott DGI. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol. 1998;37:824–36. - PubMed
-
- Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42. - PubMed
-
- Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res. 1995;55:1670–4. - PubMed
-
- Cuffari C, Seidmen EG, Latour S, Theoret Y. Quantitation of 6-thioguanine in preipheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol. 1996;74:580–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
